ArticleFrontiers in nutrition2026
The lactate-to-albumin ratio as a potential biomarker for short-term mortality risk in critically ill patients with urosepsis: a retrospective study with dual-cohort validation.
Article in Frontiers in nutrition, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Association of blood urea nitrogen to albumin ratio with short-term mortality in critically ill patients with urosepsis.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The lactate-to-albumin ratio (LAR) comprehensively reflects the nutritional status, inflammatory level, and degree of oxidative stress in critically ill patients and has been demonstrated to be associated with poor prognosis in various critical illnesses. However, its prognostic role in the specific context of urosepsis remains to be fully elucidated. Methods: This study utilized the Medical Information Mart for Intensive Care (MIMIC-IV) database as an internal discovery cohort and included an external validation cohort from Bijie Hospital of Zhejiang Provincial People's Hospital. Multivariable Cox regression, restricted cubic splines (RCS), Kaplan-Meier survival curves, and other methods were employed to analyze the association between LAR and short-term adverse outcomes in urosepsis patients. The robustness of the findings was assessed through subgroup analysis and interaction tests. Furthermore, four machine learning algorithms were combined to screen key variables for constructing a multivariable Cox risk prediction model, the performance of which was evaluated using receiver operating characteristic (ROC) curves. Results: A total of 1,055 urosepsis patients were included. The 28-day ICU mortality and in-hospital mortality rates were 20.6 and 19.1%, respectively. After multivariable adjustment, for each unit increase in LAR as a continuous variable, the hazard ratios (HR) for ICU mortality and in-hospital mortality were 1.35 (95% CI: 1.08-1.68) and 1.50 (95% CI: 1.19-1.90), respectively. When treated as a categorical variable, the high LAR group had a 73% increased risk of ICU mortality and a 71% increased risk of in-hospital mortality compared to the low LAR group. RCS analysis revealed a non-linear positive dose-response relationship between LAR and mortality. ROC analysis demonstrated that a simple risk model incorporating LAR and five other variables had superior predictive performance compared to traditional critical illness scores, and these conclusions were consistently validated in the external cohort. Conclusion: The LAR is a cost-effective supplementary predictor of short-term mortality risk in critically ill urosepsis patients, primarily aiding early identification of high-risk cases to intensify monitoring and treatment. Its clinical value require further prospective validation.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.